Hemostemix Inc. (CVE:HEM – Get Free Report) Director Peter Alan Lacey purchased 200,000 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were bought at an average cost of C$0.15 per share, with a total value of C$30,000.00.
Peter Alan Lacey also recently made the following trade(s):
- On Wednesday, February 26th, Peter Alan Lacey sold 96,464 shares of Hemostemix stock. The stock was sold at an average price of C$0.18, for a total transaction of C$16,881.20.
Hemostemix Stock Down 4.0 %
HEM stock opened at C$0.12 on Wednesday. Hemostemix Inc. has a twelve month low of C$0.04 and a twelve month high of C$0.43. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The company has a market capitalization of C$17.49 million, a P/E ratio of -3.50 and a beta of 0.20. The firm has a 50 day simple moving average of C$0.22 and a 200-day simple moving average of C$0.13.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- What is a Dividend King?
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- What is a Bond Market Holiday? How to Invest and Trade
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
